Key Takeaways Repligen has entered into an agreement to purchase BioLife Solutions through a combined cash-and-stock transaction valued at approximately $1.5 billion BioLife shareholders will
Shares of Repligen (RGEN) declined approximately 5.84% on Wednesday following the company’s announcement that it will purchase BioLife Solutions (BLFS) in a transaction valued at roughly $1.5 billion.
The transaction structure consists of 64% Repligen equity and 36% cash consideration. Shareholders of BioLife will be entitled to $11.25 cash per share along with 0.1442 shares of RGEN for every share held. This arrangement values each BioLife share at $31 — representing a 6.2% premium over BioLife’s most recent closing price.
The boards of directors at both companies have given unanimous approval to the merger. Completion is anticipated in the fourth quarter of 2026, contingent upon receiving shareholder approval and regulatory clearances.
M&A: Repligen $RGEN will acquire BioLife Solutions $BLFS for about $1.5 billion, valuing the company at $31 per share in cash and stock. The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year. pic.twitter.com/FSIkQLEIpQ
— Wall St Engine (@wallstengine) July 22, 2026
According to Repligen, the transaction will boost adjusted earnings per share by no less than $0.05 during the first year and no less than $0.25 in the second year. The company intends to finance the cash component using existing cash reserves and anticipates maintaining over $300 million in pro forma cash following the transaction’s completion.
Management forecasts minimum cost synergies of $20 million in the first year after closing, increasing to a minimum of $30 million by year two. These anticipated savings will be derived from eliminating public-company costs, enhancing general and administrative efficiency, and optimizing the supply chain.
BioLife’s primary offering is its biopreservation media platform, headlined by CryoStor. This product line currently supports 18 therapies with commercial approval and is utilized in the majority of commercially sponsored cell-based therapy trials conducted in the United States.
Additionally, BioLife contributes a suite of cell-processing technologies and a consumables business characterized by high margins and recurring revenue streams. Repligen indicated that the merger will enhance its ability to serve cell therapy customers more comprehensively, including strengthened market presence in the Asia Pacific region.
Prior to this acquisition, BioLife had been pursuing strategic simplification. In October 2025, the company divested its evo cold-chain logistics business for $25.5 million, concentrating resources on cell and gene therapy tools.
Repligen disclosed preliminary Q2 2026 revenue growth ranging from approximately 12% to 13% on an organic basis. BioLife’s preliminary Q2 revenue demonstrated approximately 21% year-over-year growth.
This acquisition follows observations from Danaher on Tuesday suggesting a resurgence in bioprocessing demand, as pharmaceutical and biotechnology companies ramp up expenditures following an extended period of reduced research activity and inventory adjustments.
The announcement also arrives roughly one month after German pharmaceutical company Merck KGaA revealed an $11.3 billion agreement to purchase Bio-Techne, another supplier to the drug development industry.
Repligen’s CEO Olivier Loeillot characterized BioLife’s portfolio as “highly differentiated” and stated the acquisition strengthens its existing presence in cell therapy. BioLife’s CEO Roderick de Greef described Repligen as an “ideal partner” due to its worldwide commercial infrastructure and complementary technology offerings.
RGEN traded down 5.84% while BLFS gained 0.34% during early Wednesday trading activity.
The post Repligen (RGEN) Shares Drop 6% Following $1.5B BioLife Solutions Acquisition Announcement appeared first on Blockonomi.
